Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2011

Open Access 01-12-2011 | Research

Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques

Authors: Kwadwo A Kusi, Edmond J Remarque, Vanessa Riasat, Vanessa Walraven, Alan W Thomas, Bart W Faber, Clemens HM Kocken

Published in: Malaria Journal | Issue 1/2011

Login to get access

Abstract

Background

Increasing the breadth of the functional antibody response through immunization with Plasmodium falciparum apical membrane antigen 1 (Pf AMA1) multi-allele vaccine formulations has been demonstrated in several rodent and rabbit studies. This study assesses the safety and immunogenicity of three Pf AMA1 Diversity-Covering (DiCo) vaccine candidates formulated as an equimolar mixture (DiCo mix) in CoVaccine HT™ or Montanide ISA 51, as well as that of a Pf AMA1-MSP119 fusion protein formulated in Montanide ISA 51.

Methods

Vaccine safety in rhesus macaques was monitored by animal behaviour observation and assessment of organ and systemic functions through clinical chemistry and haematology measurements. The immunogenicity of vaccine formulations was assessed by enzyme-linked immunosorbent assays and in vitro parasite growth inhibition assays with three culture-adapted P. falciparum strains.

Results

These data show that both adjuvants were well tolerated with only transient changes in a few of the chemical and haematological parameters measured. DiCo mix formulated in CoVaccine HT™ proved immunologically and functionally superior to the same candidate formulated in Montanide ISA 51. Immunological data from the fusion protein candidate was however difficult to interpret as four out of six immunized animals were non-responsive for unknown reasons.

Conclusions

The study highlights the safety and immunological benefits of DiCo mix as a potential human vaccine against blood stage malaria, especially when formulated in CoVaccine HT™, and adds to the accumulating data on the specificity broadening effects of DiCo mix.
Appendix
Available only for authorised users
Literature
1.
Escalante AA, Lal AA, Ayala FJ: Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics. 1998, 149: 189-202.PubMedCentralPubMed
2.
Polley SD, Conway DJ: Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics. 2001, 158: 1505-1512.PubMedCentralPubMed
3.
Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, Bodescot M, Rubinstein E, Hannoun L, Charoenvit Y, Kocken CH, Thomas AW, Geert-Jan van Gemert GJ, Sauerwein RW, Blackman MJ, Anders RF, Pluschke G, Mazier D: A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem. 2004, 279: 9490-9496. 10.1074/jbc.M311331200.CrossRefPubMed
4.
Thomas AW, Waters AP, Carr D: Analysis of variation in PF83, an erythrocytic merozoite vaccine candidate antigen of Plasmodium falciparum. Mol Biochem Parasitol. 1990, 42: 285-287. 10.1016/0166-6851(90)90172-I.CrossRefPubMed
5.
Narum DL, Thomas AW: Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol. 1994, 67: 59-68. 10.1016/0166-6851(94)90096-5.CrossRefPubMed
6.
Bannister LH, Hopkins JM, Dluzewski AR, Margos G, Williams IT, Blackman MJ, Kocken CH, Thomas AW, Mitchell GH: Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite development. J Cell Sci. 2003, 116: 3825-3834. 10.1242/jcs.00665.CrossRefPubMed
7.
Healer J, Crawford S, Ralph S, McFadden G, Cowman AF: Independent translocation of two micronemal proteins in developing Plasmodium falciparum merozoites. Infect Immun. 2002, 70: 5751-5758. 10.1128/IAI.70.10.5751-5758.2002.PubMedCentralCrossRefPubMed
8.
Mitchell GH, Thomas AW, Margos G, Dluzewski AR, Bannister LH: Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect Immun. 2004, 72: 154-158. 10.1128/IAI.72.1.154-158.2004.PubMedCentralCrossRefPubMed
9.
Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, Crabb BS, Cowman AF: Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol. 2000, 38: 706-718. 10.1046/j.1365-2958.2000.02175.x.CrossRefPubMed
10.
Howell SA, Withers-Martinez C, Kocken CH, Thomas AW, Blackman MJ: Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J Biol Chem. 2001, 276: 31311-31320. 10.1074/jbc.M103076200.CrossRefPubMed
11.
Hodder AN, Crewther PE, Matthew ML, Reid GE, Moritz RL, Simpson RJ, Anders RF: The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem. 1996, 271: 29446-29452. 10.1074/jbc.271.46.29446.CrossRefPubMed
12.
Goel VK, Li X, Chen H, Liu SC, Chishti AH, Oh SS: Band 3 is a host receptor binding merozoite surface protein 1 during the Plasmodium falciparum invasion of erythrocytes. Proc Natl Acad Sci USA. 2003, 100: 5164-5169. 10.1073/pnas.0834959100.PubMedCentralCrossRefPubMed
13.
O'Donnell RA, Saul A, Cowman AF, Crabb BS: Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species. Nat Med. 2000, 6: 91-95. 10.1038/71595.CrossRefPubMed
14.
Qari SH, Shi YP, Goldman IF, Nahlen BL, Tibayrenc M, Lal AA: Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. Mol Biochem Parasitol. 1998, 92: 241-252. 10.1016/S0166-6851(98)00010-3.CrossRefPubMed
15.
Tolle R, Bujard H, Cooper JA: Plasmodium falciparum: variations within the C-terminal region of merozoite surface antigen-1. Exp Parasitol. 1995, 81: 47-54. 10.1006/expr.1995.1091.CrossRefPubMed
16.
Holder AA, Blackman MJ, Burghaus PA, Chappel JA, Ling IT, McCallum-Deighton N, Shai S: A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswaldo Cruz. 1992, 87 (Suppl 3): 37-42.CrossRefPubMed
17.
Blackman MJ, Whittle H, Holder AA: Processing of the Plasmodium falciparum major merozoite surface protein-1: identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion. Mol Biochem Parasitol. 1991, 49: 35-44. 10.1016/0166-6851(91)90128-S.CrossRefPubMed
18.
Holder AA, Sandhu JS, Hillman Y, Davey LS, Nicholls SC, Cooper H, Lockyer MJ: Processing of the precursor to the major merozoite surface antigens of Plasmodium falciparum. Parasitology. 1987, 94 (Pt 2): 199-208.CrossRefPubMed
19.
Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA: A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med. 1990, 172: 379-382. 10.1084/jem.172.1.379.CrossRefPubMed
20.
Blackman MJ, Ling IT, Nicholls SC, Holder AA: Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol. 1991, 49: 29-33. 10.1016/0166-6851(91)90127-R.CrossRefPubMed
21.
Anders RF, Crewther PE, Edwards S, Margetts M, Matthew ML, Pollock B, Pye D: Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine. 1998, 16: 240-247. 10.1016/S0264-410X(97)88331-4.CrossRefPubMed
22.
Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, Vassell MA, Fileta BB, Kitov S, Kolodny N, Heppner DG, Haynes JD, Lanar DE: Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun. 2002, 70: 3101-3110. 10.1128/IAI.70.6.3101-3110.2002.PubMedCentralCrossRefPubMed
23.
Hodder AN, Crewther PE, Anders RF: Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun. 2001, 69: 3286-3294. 10.1128/IAI.69.5.3286-3294.2001.PubMedCentralCrossRefPubMed
24.
Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, Robinson SJ, Bergmann-Leitner ES, Duncan EH, Darko CA, Collins WE, Long CA, Barnwell JW: Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS ONE. 2008, 3: e2830-10.1371/journal.pone.0002830.PubMedCentralCrossRefPubMed
25.
Narum DL, Ogun SA, Thomas AW, Holder AA: Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun. 2000, 68: 2899-2906. 10.1128/IAI.68.5.2899-2906.2000.PubMedCentralCrossRefPubMed
26.
Singh S, Miura K, Zhou H, Muratova O, Keegan B, Miles A, Martin LB, Saul AJ, Miller LH, Long CA: Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun. 2006, 74: 4573-4580. 10.1128/IAI.01679-05.PubMedCentralCrossRefPubMed
27.
Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH: Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun. 2002, 70: 6961-6967. 10.1128/IAI.70.12.6961-6967.2002.PubMedCentralCrossRefPubMed
28.
Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA: Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med. 1994, 180: 389-393. 10.1084/jem.180.1.389.CrossRefPubMed
29.
Dutta S, Haynes JD, Moch JK, Barbosa A, Lanar DE: Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci USA. 2003, 100: 12295-12300. 10.1073/pnas.2032858100.PubMedCentralCrossRefPubMed
30.
Collins WE, Pye D, Crewther PE, Vandenberg KL, Galland GG, Sulzer AJ, Kemp DJ, Edwards SJ, Coppel RL, Sullivan JS, Morris CL, Anders RF: Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg. 1994, 51: 711-719.PubMed
31.
Crewther PE, Matthew ML, Flegg RH, Anders RF: Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun. 1996, 64: 3310-3317.PubMedCentralPubMed
32.
Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA, Miller LH, Stowers AW: In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun. 2002, 70: 6948-6960. 10.1128/IAI.70.12.6948-6960.2002.PubMedCentralCrossRefPubMed
33.
Remarque EJ, Faber BW, Kocken CH, Thomas AW: A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun. 2008, 76: 2660-2670. 10.1128/IAI.00170-08.PubMedCentralCrossRefPubMed
34.
Kusi KA, Faber BW, Riasat V, Thomas AW, Kocken CH, Remarque EJ: Generation of humoral immune responses to multi-allele Pf AMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. PLoS ONE. 2010, 5: e15391-10.1371/journal.pone.0015391.PubMedCentralCrossRefPubMed
35.
Faber BW, Remarque EJ, Morgan WD, Kocken CH, Holder AA, Thomas AW: Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. Infect Immun. 2007, 75: 5947-5955. 10.1128/IAI.01804-06.PubMedCentralCrossRefPubMed
36.
Burns JM, Flaherty PR, Romero MM, Weidanz WP: Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1. Vaccine. 2003, 21: 1843-1852. 10.1016/S0264-410X(03)00026-4.CrossRefPubMed
37.
Langermans JA, Schmidt A, Vervenne RA, Birkett AJ, Calvo-Calle JM, Hensmann M, Thornton GB, Dubovsky F, Weiler H, Nardin E, Thomas AW: Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques. Vaccine. 2005, 23: 4935-4943. 10.1016/j.vaccine.2005.05.036.CrossRefPubMed
38.
Kusi KA, Faber BW, Thomas AW, Remarque EJ: Humoral immune response to mixed Pf AMA1 alleles; multivalent Pf AMA1 vaccines induce broad specificity. PLoS ONE. 2009, 4: e8110-10.1371/journal.pone.0008110.PubMedCentralCrossRefPubMed
39.
40.
Mullen GE, Giersing BK, Ajose-Popoola O, Davis HL, Kothe C, Zhou H, Aebig J, Dobrescu G, Saul A, Long CA: Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine. 2006, 24: 2497-2505. 10.1016/j.vaccine.2005.12.034.CrossRefPubMed
41.
Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, Iasonos A, Lee H, Dupont B, Pezzulli S, Jungbluth AA, Old LJ, Dupont J: Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res. 2008, 14: 2740-2748. 10.1158/1078-0432.CCR-07-4619.CrossRefPubMed
42.
Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, Smith C, Ginsberg R, Eldridge J, Duerr A, Fast P, Haynes BF, the AIDS Vaccine Evaluation Group: Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS ONE. 2010, 5: e11995-10.1371/journal.pone.0011995.PubMedCentralCrossRefPubMed
43.
Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura M, Long C, Saul A, Miller LH, Durbin AP: Phase 1 trial of malaria transmission blocking vaccine candidates Pf s25 and Pv s25 formulated with montanide ISA 51. PLoS ONE. 2008, 3: e2636-10.1371/journal.pone.0002636.PubMedCentralCrossRefPubMed
44.
45.
Gonzalez Gil A, Illera JC, Silvan G, Illera M: Effects of the anaesthetic/tranquillizer treatments on selected plasma biochemical parameters in NZW rabbits. Laboratory Animals. 2003, 37: 155-161. 10.1258/00236770360563804.CrossRefPubMed
46.
Wyatt JD, Scott RA, Richardson ME: The effects of prolonged ketamine-xylazine intravenous infusion on arterial blood pH, blood gases, mean arterial blood pressure, heart and respiratory rates, rectal temperature and reflexes in the rabbit. Lab Anim Sci. 1989, 39: 411-416.PubMed
47.
Heldens JG, Glansbeek HL, Hilgers LA, Haenen B, Stittelaar KJ, Osterhaus AD, van den Bosch JF: Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits. Vaccine. 2010, 28: 8125-8131. 10.1016/j.vaccine.2010.09.097.CrossRefPubMed
48.
Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AVS: Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol. 2010, 185: 7583-7595. 10.4049/jimmunol.1001760.CrossRefPubMed
49.
Bodewes R, Kreijtz JH, van Amerongen G, Geelhoed-Mieras MM, Verburgh RJ, Heldens JG, Bedwell J, van den Brand JM, Kuiken T, van Baalen CA, Fouchier RAM, Osterhaus ADME, Rimmelzwaan GF: A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J Virol. 2010, 84: 7943-7952. 10.1128/JVI.00549-10.PubMedCentralCrossRefPubMed
50.
Johnson SM, Lerche NW, Pappagianis D, Yee JL, Galgiani JN, Hector RF: Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). Ann N Y Acad Sci. 2007, 1111: 290-300. 10.1196/annals.1406.042.CrossRefPubMed
51.
Morera Y, Bequet-Romero M, Ayala M, Velazco JC, Perez PP, Alba JS, Ancizar J, Rodriguez M, Cosme K, Gavilondo JV: Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine. 2010, 28: 3453-3461. 10.1016/j.vaccine.2010.02.069.CrossRefPubMed
52.
Herrera S, Fernandez OL, Vera O, Cardenas W, Ramirez O, Palacios R, Chen-Mok M, Corradin G, Arevalo-Herrera M: Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am J Trop Med Hyg. 2011, 84: 12-20. 10.4269/ajtmh.2011.09-0516.PubMedCentralCrossRefPubMed
53.
Pan W, Huang D, Zhang Q, Qu L, Zhang D, Zhang X, Xue X, Qian F: Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. J Immunol. 2004, 172: 6167-6174.CrossRefPubMed
54.
Arnot DE, Cavanagh DR, Remarque EJ, Creasey AM, Sowa MP, Morgan WD, Holder AA, Longacre S, Thomas AW: Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum. Clin Vaccine Immunol. 2008, 15: 1345-1355. 10.1128/CVI.00172-08.PubMedCentralCrossRefPubMed
55.
Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, Soisson L, Diggs CL, Heppner DG, Lanar DE, Collins WE, Barnwell JW: High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS ONE. 2009, 4: e8138-10.1371/journal.pone.0008138.PubMedCentralCrossRefPubMed
56.
Jones TR, Obaldia N, Gramzinski RA, Hoffman SL: Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. Am J Trop Med Hyg. 2000, 62: 675-680.PubMed
Metadata
Title
Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques
Authors
Kwadwo A Kusi
Edmond J Remarque
Vanessa Riasat
Vanessa Walraven
Alan W Thomas
Bart W Faber
Clemens HM Kocken
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2011
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-10-182

Other articles of this Issue 1/2011

Malaria Journal 1/2011 Go to the issue

Research

Target product profile choices for intra-domiciliary malaria vector control pesticide products: repel or kill?

Research

Reduced risk for placental malaria in iron deficient women

Research

Mapping of mosquito breeding sites in malaria endemic areas in Pos Lenjang, Kuala Lipis, Pahang, Malaysia

Research

Outdoor host seeking behaviour of Anopheles gambiae mosquitoes following initiation of malaria vector control on Bioko Island, Equatorial Guinea

Research

Laboratory selection for an accelerated mosquito sexual development rate

Research

Congenital malaria in Urabá, Colombia
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits